Neurocrine (NBIX) Chief Scientific Officer gifts 3,110 company shares

Rhea-AI Filing Summary

Neurocrine Biosciences Chief Scientific Officer makes charitable stock gift

Neurocrine Biosciences’ Chief Scientific Officer, Jude Onyia, reported a bona fide gift of 3,110 shares of common stock effective February 20, 2026. The filing states this was a gift/charitable contribution, not a market transaction, so no price or proceeds were involved. After the transfer, Onyia directly holds 25,670 shares of Neurocrine Biosciences common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Onyia Jude

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		G(1)		3,110	D	$0	25,670	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction represents a gift/charitable contribution effective February 20, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Neurocrine Biosciences (NBIX) executive Jude Onyia report on this Form 4?

Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences, reported a bona fide gift of 3,110 shares of common stock. The transaction was effective February 20, 2026 and left him with 25,670 directly held shares after the disposition.

Was the NBIX Form 4 transaction a market sale of shares?

No, the transaction was not a market sale. The filing specifies it as a bona fide gift or charitable contribution, with no price reported and no value received for the 3,110 common shares transferred on February 20, 2026.

How many Neurocrine Biosciences shares did Jude Onyia gift?

Jude Onyia gifted 3,110 shares of Neurocrine Biosciences common stock. According to the Form 4, this transfer was reported under transaction code “G” for a bona fide gift and did not involve any consideration or market trading activity.

How many NBIX shares does Jude Onyia hold after the reported gift?

Following the reported gift, Jude Onyia directly holds 25,670 shares of Neurocrine Biosciences common stock. This total reflects his remaining direct ownership after transferring 3,110 shares as a bona fide gift or charitable contribution on February 20, 2026.

Did Jude Onyia receive any compensation for the gifted NBIX shares?

No, the filing states that no value was received for the gifted shares. The 3,110 Neurocrine Biosciences common shares were transferred as a bona fide gift or charitable contribution, and no transaction price per share was reported on the Form 4.

What does transaction code “G” mean in this NBIX Form 4 filing?

Transaction code “G” on the Form 4 denotes a bona fide gift. In this case, it indicates that 3,110 Neurocrine Biosciences common shares were transferred by Jude Onyia as a gift or charitable contribution, rather than being sold in the open market.